EureKare

EureKare is a venture capital firm based in Senningerberg, Luxembourg, founded in 2020. The company specializes in investing in synthetic biology biotechnology companies and aims to create new ventures within this innovative field. EureKare focuses on the synthetic biotechnology industries across Europe, seeking to support and develop groundbreaking technologies that can advance healthcare and related sectors. Through its investments, EureKare is committed to fostering advancements in biotechnology that leverage synthetic biology to address various challenges in the industry.

4 past transactions

DNA Script

Series C in 2022
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Gynov

Corporate Round in 2021
Gynov focuses on the development of innovative solutions dedicated to women's health issues.

Coave Therapeutics

Series B in 2021
Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.

Omne Possibile

Seed Round in 2021
Omne Possibile is a technology that will outperform current DNA and RNA technologies. They offer the transformative power of XNA in areas including healthcare, information technology, and smart materials. They provide services for XNA development: chemical synthesis, genetics, directed evolution of enzymes and genomes, automated design of molecules, and bioproduction pathways.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.